

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
GenoClipp Biotechnology B.V.	07/26/2006
RECEIVING PARTY DATA	
Name:	Institute for OneWorld Health
Street Address:	50 California St.
Internal Address:	Suite 500
City:	San Francisco
State/Country:	CALIFORNIA
Postal Code:	94111
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	09763822
CORRESPONDENCE DATA	
Fax Number:	(412)471-4094
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	412-471-8815
Email:	webblaw@webblaw.com
Correspondent Name:	The Webb Law Firm
Address Line 1:	436 Seventh Avenue
Address Line 2:	700 Koppers Building
Address Line 4:	Pittsburgh, PENNSYLVANIA 15219
ATTORNEY DOCKET NUMBER:	0702-010272
NAME OF SUBMITTER:	Barbara E. Johnson, 0702-010272
Total Attachments: 1 source=w0294688#page1.tif	

OP \$40.00 09763822

500142053

PATENT
REEL: 018156 FRAME: 0969

ASSIGNMENT

WHEREAS, GenoClipp Biotechnology B.V., a corporation of The Netherlands, having a place of business at L.J. Zielstraweg 1, NL-9713 GX Groningen, The Netherlands, hereinafter called the "assignor", is the owner of certain new and useful improvements entitled "Transgenic Amorpha-4, 11-Diene Synthesis" for which a patent application was filed in the United States Patent and Trademark Office on April 24, 2001 and bears Serial No. 09/763,822;

AND, WHEREAS, Institute for OneWorld Health, a corporation of California, having a place of business at 50 California St., Suite 500, San Francisco, CA 94111, hereinafter called the "assignee", is desirous of acquiring the entire right, title, and interest in and to said application and the inventions and improvements therein disclosed.

NOW, THEREFORE, for good and valuable consideration paid to assignor by said assignee, the receipt of which is hereby acknowledged, assignor does hereby assign, sell, transfer, and set over unto said assignee the entire right, title and interest in and to said application and the inventions and improvements therein disclosed for the United States and all foreign countries and any Letters Patent which may issue therefor in the United States and all foreign countries and all divisions, reissues, continuations, continuations-in-part, renewals, and/or extensions thereof, said assignee to have and to hold the interests herein assigned to the full ends of the terms of said Letters Patent and any and all divisions, reissues, continuations, continuations-in-part, renewals, and/or extensions thereof, respectively, as fully and entirely as the same would have been held and enjoyed by assignor had this assignment not been made.

The Commissioner for Patents is requested to issue such Letters Patent in accordance herewith. Assignor covenants that it is the lawful owner of the said application, inventions, and improvements, that the same are unencumbered, that no license has been granted to make, use, or vend the said inventions or improvements or any of them, and that assignor has the full right to make this assignment.

And for the consideration aforesaid, assignor agrees that it will communicate to said assignee or the representatives thereof any facts known to assignor respecting said inventions and improvements, and will, upon request, but without expense to assignor, testify in any legal proceedings, sign all lawful papers, execute all divisional, reissue, continuation, continuation-in-part, renewal, and/or extension applications, make all rightful oaths, and generally do all other and further lawful acts, deemed necessary or expedient by said assignee or by counsel for said assignee, to assist or enable said assignee to obtain and enforce full benefits from the rights and interests herein assigned. This assignment shall be binding upon assignor's heirs, executors, administrators, and/or assigns, and shall inure to the benefit of the heirs, executors and administrators, as the case may be, of said assignee.

Dated 07-26-2006

By [Signature]
Officer of
Genoclipp Biotechnology B.V.

C.A. Maijers
Title

Chief Executive Director

{W0260197.1}